{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:31:40Z","timestamp":1767771100075},"reference-count":20,"publisher":"Asia Pacific Academy of Ophthalmology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia Pac J Ophthalmol (Phila)"],"published-print":{"date-parts":[[2019]]},"DOI":"10.22608\/apo.2017466","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T09:24:23Z","timestamp":1510219463000},"source":"Crossref","is-referenced-by-count":6,"title":["Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lectur"],"prefix":"10.22608","member":"9895","published-online":{"date-parts":[[2019]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/414782a"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(84)34102-1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1111"},{"key":"ref4","first-page":"331","article-title":"Medical interventions for diabetic retinopathy.","volume-title":"Evidence-Based Ophthalmology","author":"Richter","year":"2004","unstructured":"4. Richter B, Kohner E. Medical interventions for diabetic retinopathy. In: Wormald R, Smeeth L, Henshaw K, eds. Evidence-Based Ophthalmology. London: BMJ Books; 2004:331\u2012340."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)75794-0"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199412013312203"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1994.01090230090028"},{"key":"ref8","first-page":"638","article-title":"Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.","volume":"72","author":"Pe'er","year":"1995","unstructured":"8. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72:638\u2012645.","journal-title":"Lab Invest","ISSN":"http:\/\/id.crossref.org\/issn\/0023-6837","issn-type":"print"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.11.045"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307950"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.12.025"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.022"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.393"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.02.034"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001181"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15217"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.127142"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.05.015"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S37458"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2013.0832"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T23:04:57Z","timestamp":1561763097000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/apjoo\/Fulltext\/2018\/01000\/Intravitreal_Bevacizumab_in_Diabetic_Retinopathy_.6.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":20,"URL":"https:\/\/doi.org\/10.22608\/apo.2017466","relation":{},"ISSN":["2162-0989","2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"},{"value":"2162-0989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}